基质金属蛋白酶-2活性与成釉细胞瘤增殖生长关系的研究

目的 探讨基质金属蛋白酶-2（MMP-2）活性与成釉细胞瘤增殖生长的关系及其在成釉细胞瘤侵袭中的作用。方法 通过MMP-2抑制剂Ro31-9790抑制MMP-2活性进行干预处理，采用成釉细胞瘤细胞原代培养、瘤组织块裸鼠肾包膜下移植、MTT、流式细胞术、瘤体积测量和组织学检查等方法，观察MMP-2活性与成釉细胞瘤增殖生长的关系。结果 实验各组之间在同一时间点的细胞增殖活性均无显著性差异（P＞0.05）。G0/G1、G2/M期细胞比率以及凋亡细胞比率不随Ro31-9790浓度增加而增加，S期细胞比率也不随Ro31-9790浓度增加而减少。Ro31-9790治疗组瘤体积明显小于对照组（P＜0.05），瘤体积增加也明显少于对照组（P＜0.01）。结论 Ro31-9790对成釉细胞瘤细胞的体外增殖活性无影响，但可抑制体内移植瘤的生长，MMP-2活性与成釉细胞瘤细胞的增殖活性无关，但与成釉细胞瘤的生长密切相关，可能是成釉细胞瘤局部侵袭的机制之一。

Association of Matrix Metalloproteinase-2 Activity with Cell Proliferation and Growth in Ameloblastoma

Objective To investigate the relationship between matrix metalloproteinase-( 2 MMP- 2)activity and cell proliferation, growth and invasion of ameloblastoma. Methods The cells and xenograft of ameloblastoma were treated with MMP- 2 inhibitor Ro31- 9790 and the effects of Ro31- 9790 on the cell proliferation and growth of ameloblas- toma were observed. Primary culture in vitro, subcapsular kidney xenograft in vivo, MTT assay, flow cytometry, neo- plasitc volume measurement and histochemistry were employed to study the effects of cell proliferation and growth produced by Ro31- 9790. Results There was no significant different in cell proliferation at same interval among several groups (P>0.05). The ratio of G0/G1 stage, G2/M stage and apoptotic cells didn't increase following increased Ro31- 9790, and the ratio of S stage cells also didn't reduce following increased Ro31- 9790. The tumor volume and its increase in treatment group were significant less than those in control group. Conclusion Ro31- 9790 does not influence proliferation of ameloblastoma cells in vitro, but it can effectively inhibit the ameloblastoma growth in vvo. MMP- 2 activity has no relationship to proliferation of ameloblastoma cells, but it can contribute to the ameloblas- toma growth and may be a reason of invasion in ameloblastoma.